Ibrance 125 mg is prescribed by an oncologist for the treatment of locally advanced or metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer: 🔹 In combination with an aromatase inhibitor: As first-line endocrine therapy in postmenopausal women. 🔹 In combination with fulvestrant: In women whose disease has progressed after prior hormonal therapy.

Dosage and administration

Sales Form: 1 bottle contains 21 capsules of 125 mg (designed for one full course/cycle).⚠️ INSTRUCTIONS FOR USE: Cyclic Regimen: The standard dosing schedule is 1 capsule (125 mg) once daily for 21 consecutive days, followed by a mandatory 7-day break (21/7 cycle). Method: The capsule should be taken with food (this ensures stable drug concentration), preferably at the same time each day. The capsule must not be opened or chewed. Blood Monitoring: Before starting each cycle and in the middle of the first few cycles, a complete blood count is necessary to monitor neutrophil levels (white blood cells). Storage: Store at 15–30°C in the original packaging.

⛔ Individual Intolerance: Hypersensitivity to palbociclib. ⛔ Pregnancy and Lactation: The drug can cause fetal harm. Strictly contraindicated. Reliable contraception must be used during and for 3 weeks after treatment. ⛔ Age: Not used for the treatment of children and adolescents under 18 years of age. ⛔ Interactions: Do not consume grapefruit or grapefruit juice during treatment, as they can significantly increase the drug level in the blood and cause toxicity. ⛔ Infections: Severe active infectious diseases.

When using Ibrance 125 mg, the most common observations are changes in the hematopoietic system: 🩸 Neutropenia: Decrease in neutrophil levels (observed in most patients, but usually managed by a treatment break). Anemia and thrombocytopenia are also possible. 💪 General Symptoms: Increased fatigue, weakness, dizziness. 🤢 Digestion: Nausea, diarrhea, stomatitis (mouth sores), decreased appetite. 💇♀️ Appearance: Thinning or partial loss of hair (alopecia), dry skin, rash. ⚠️ Important: If a fever develops or signs of a cold appear while taking the medication, contact your treating physician immediately.

Ibrance 125 — Palbociclib 125 mg, 21 pcs, Pfizer

100% original product

Active ingredient

Palbociclib

Manufacturer

Pfizer

Dosage

125 mg

Dosage form Capsules

Capsules per pack 21

Ibrance 125 — Palbociclib 125 mg (21 Capsules)

Name: Ibrance 125
Brand: Pfizer
SKU: PROD-288
Price: 44700 UAH
Availability: PreOrder

44700₴ ~~49170₴~~ -9% On order · from 7 days

Analogues

Ibrance 125 Palbocent 125 Palbocib Palbotiz Palboxen Palnat 125 Piclib

Active ingredient

Palbociclib

Manufacturer

Pfizer

Dosage

125 mg

Dosage form Capsules

Capsules per pack 21

Ibrance 125 mg (Palbociclib) is an innovative targeted medication used to treat specific types of metastatic breast cancer. Palbociclib is a first-in-class inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). By blocking these proteins, the drug slows the division of tumor cells and prevents disease progression, significantly increasing progression-free survival when used in combination with hormonal therapy.

Manufacturer: Pfizer, USA. Ibrance has made a breakthrough in oncology, becoming a standard of therapy for patients with hormone-receptor-positive cancer, allowing for long-term disease control while maintaining quality of life.

Key Features:

✅ Cycle Control Mechanism: Selectively blocks the transition of cancer cells from the resting phase to the division phase.
✅ Synergy with Hormone Therapy: Enhances the effect of aromatase inhibitors and fulvestrant, overcoming tumor resistance.
✅ Convenience of Use: The oral form in a 125 mg dosage is the standard starting dose for most patients.

Ibrance 125 mg is prescribed by an oncologist for the treatment of locally advanced or metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer:

🔹 In combination with an aromatase inhibitor: As first-line endocrine therapy in postmenopausal women.
🔹 In combination with fulvestrant: In women whose disease has progressed after prior hormonal therapy.

Sales Form: 1 bottle contains 21 capsules of 125 mg (designed for one full course/cycle).

⚠️ INSTRUCTIONS FOR USE:

Cyclic Regimen: The standard dosing schedule is 1 capsule (125 mg) once daily for 21 consecutive days, followed by a mandatory 7-day break (21/7 cycle).
Method: The capsule should be taken with food (this ensures stable drug concentration), preferably at the same time each day. The capsule must not be opened or chewed.
Blood Monitoring: Before starting each cycle and in the middle of the first few cycles, a complete blood count is necessary to monitor neutrophil levels (white blood cells).
Storage: Store at 15–30°C in the original packaging.

⛔ Individual Intolerance: Hypersensitivity to palbociclib.
⛔ Pregnancy and Lactation: The drug can cause fetal harm. Strictly contraindicated. Reliable contraception must be used during and for 3 weeks after treatment.
⛔ Age: Not used for the treatment of children and adolescents under 18 years of age.
⛔ Interactions: Do not consume grapefruit or grapefruit juice during treatment, as they can significantly increase the drug level in the blood and cause toxicity.
⛔ Infections: Severe active infectious diseases.

When using Ibrance 125 mg, the most common observations are changes in the hematopoietic system:

🩸 Neutropenia: Decrease in neutrophil levels (observed in most patients, but usually managed by a treatment break). Anemia and thrombocytopenia are also possible.
💪 General Symptoms: Increased fatigue, weakness, dizziness.
🤢 Digestion: Nausea, diarrhea, stomatitis (mouth sores), decreased appetite.
💇‍♀️ Appearance: Thinning or partial loss of hair (alopecia), dry skin, rash.
⚠️ Important: If a fever develops or signs of a cold appear while taking the medication, contact your treating physician immediately.

On order · from 7 days

100% original product

Delivery across Ukraine

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 22.04.2026